---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-25-000167"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2025-12-16T23:59:59+00:00"
generated_at: "2026-05-16T13:07:50.175008+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pfizer revises FY2025 revenue to ~$62B (from $61-64B), provides FY2026 EPS guidance $2.80-3.00

## Summary
- Revised FY2025 revenue guidance to ~$62.0B from prior $61-64B; reaffirmed adjusted diluted EPS $3.00-3.15.
- FY2026 revenue guidance $59.5-62.5B; adjusted diluted EPS $2.80-3.00; tax rate ~15% vs ~11%.
- COVID-19 product revenues ~$5.0B in 2026 (vs ~$6.5B in 2025); LOE impact ~$1.5B.
- Adjusted SI&A $12.5-13.5B, R&D $10.5-11.5B in 2026; investing in PD-1 x VEGF bispecific and Metsera programs.

## SEC filing metadata
- accession: 0000078003-25-000167
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2025-12-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800325000167/0000078003-25-000167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800325000167/pfe-20251216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-25-000167
- JSON: https://secwatch.observer/filing/0000078003-25-000167.json
- Plain text: https://secwatch.observer/filing/0000078003-25-000167.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.